Patents Assigned to Inex Pharmaceuticals Corp.
-
Patent number: 7094423Abstract: Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation.Type: GrantFiled: July 14, 2000Date of Patent: August 22, 2006Assignee: INEX Pharmaceuticals Corp.Inventors: Norbert Maurer, Kim F Wong, Pieter R. Cullis
-
Publication number: 20050079212Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: ApplicationFiled: October 1, 2004Publication date: April 14, 2005Applicant: Inex Pharmaceuticals Corp.Inventors: Jeffery Wheeler, Michael Hope, Pieter Cullis, Marcel Bally
-
Patent number: 6815432Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: GrantFiled: February 24, 2003Date of Patent: November 9, 2004Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
-
Patent number: 6734171Abstract: The present invention relates to lipid-based formulations for nucleic acid delivery to cells, methods for the preparation of such formulations and, in particular, to lipid encapsulated plasmids. The compositions are safe and practical for clinical use. In addition, the present invention provides methods for introducing nucleic acids into cells and for inhibiting tumor growth in cells using such lipid-nucleic acid formulations.Type: GrantFiled: October 9, 1998Date of Patent: May 11, 2004Assignee: Inex Pharmaceuticals Corp.Inventors: Edward George Saravolac, Yuan-Peng Zhang, Jeffery J. Wheeler, Pieter R. Cullis, Peter Scherrer, Ljiljana D. Kojic, Olga Ludkovski
-
Publication number: 20030181410Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: ApplicationFiled: February 24, 2003Publication date: September 25, 2003Applicant: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
-
Patent number: 6534484Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: GrantFiled: November 8, 1999Date of Patent: March 18, 2003Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
-
Patent number: 6320017Abstract: The present invention relates to new polyamide oligomers. These oligomers can be conjugated to lipids, nucleic acids, peptides, proteins, etc. The oligomer-lipid conjugates can be used to form liposomes, virusomes, micelles, etc., optionally containing drugs or biological agents. The polyamide oligomers are heterobifunctional allowing the attachment of other suitable ligand compounds (e.g., a targeting moiety). In addition, methods of use for the liposomes, virusomes, micelles, etc., are provided.Type: GrantFiled: December 22, 1998Date of Patent: November 20, 2001Assignee: INEX Pharmaceuticals Corp.Inventor: Steven Michial Ansell
-
Patent number: 6287591Abstract: Lipid-therapeutic agent particles are prepared containing a charged therapeutic agent encapsulated in lipid portion containing at least two lipid components including a protonatable or deprotonatable lipid such as an amino lipid and a lipid that prevents particle aggregation during lipid-therapeutic agent particle formation such as a PEG-modified or polyamide oligomer-modified lipid. Other lipid components may also be present and these include a neutral lipid such as DSPC, POPC, DOPE or SM, and a sterol such as Chol. The therapeutic agent is encapsulated by combining a mixture of the lipids with a buffered aqueous solution of a charged therapeutic agent to form an intermediate mixture containing lipid-encapsulated therapeutic agent particles, and changing the pH of the intermediate mixture to neutralize at least some surface charges on the particles. The method permits high ratios of therapeutic agent to lipid and encapsulation efficiencies in excess of 50%.Type: GrantFiled: May 14, 1998Date of Patent: September 11, 2001Assignee: Inex Pharmaceuticals Corp.Inventors: Sean C. Semple, Sandra K. Klimuk, Troy Harasym, Michael J. Hope, Steven M. Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
-
Patent number: 6110745Abstract: This invention relates to a novel Solvent Extraction and Direct Hydration (SEDH) method for preparing lipid-nucleic acid particles which are useful for the introduction of nucleic acids (e.g., plasmid DNA, antisense molecules, ribozymes, etc.) into cells. The lipid-nucleic acid particles prepared using the methods of the present invention have enhanced circulation characteristics and serum stability and, thus, they are extremely effective as nucleic acid delivery vehicles.Type: GrantFiled: July 23, 1998Date of Patent: August 29, 2000Assignee: Inex Pharmaceuticals Corp.Inventors: Yuan-Peng Zhang, Peter Scherrer, Michael J. Hope
-
Patent number: 5981501Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: GrantFiled: June 7, 1995Date of Patent: November 9, 1999Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
-
Patent number: 5976567Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.Type: GrantFiled: June 6, 1996Date of Patent: November 2, 1999Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope, Pieter R. Cullis, Peter Scherrer
-
Patent number: 5965542Abstract: Methods of forming cationic liposome/nucleic acid complexes in which the complexes have a mean diameter of about 200 to about 300 nm are provided. The complexes are formed by combining a first solution of preformed cationic unilamellar liposomes with a mean diameter of from 100 to 150 nm, with a second solution of nucleic acid. Each of the solutions are equilibrated prior to mixing to temperatures of from 0.degree. C. to about 12.degree. C., preferably about 2.degree. C. to about 7.degree. C. The preformed cationic liposomes are typically prepared from an unsaturated cationic lipid, for example DODAC, DOTAP, DOTMA, DODAP, DMRIE, DORI, DOSPA and combinations thereof, and a neutral lipid, for example DOPE or cholesterol. The combination of the first and second solutions is typically carried out by gentle mixing over ice for a period of time of from about 10 to about 60 minutes.Type: GrantFiled: March 18, 1997Date of Patent: October 12, 1999Assignee: Inex Pharmaceuticals Corp.Inventors: Ellen K. Wasan, Marcel B. Bally, Michael J. Hope, Dorothy L. Reimer, Quet Fah Ahkong
-
Patent number: 5785992Abstract: The present invention provides compositions and methods which are useful for the introduction of polyanionic materials into cells. The compositions are mixtures of cationic compounds and neutral lipids which are typically formulated as liposomes. The cationic compounds are quaternary ammonium compounds wherein the nitrogen has two attached long chain alkyl groups, at least one of which is unsaturated. The methods for transfecting cells involve (a) contacting the polyanionic materials with the compositions above to form a polyanionic material-liposome complex, and (b) contacting the complex with the cells to be transfected.Type: GrantFiled: September 29, 1995Date of Patent: July 28, 1998Assignee: Inex Pharmaceuticals Corp.Inventors: Steven Michial Ansell, Barbara Mui, Michael Hope
-
Patent number: 5478860Abstract: Microemulsion compositions for the delivery of hydrophobic compounds are provided. Such compositions have a variety of uses. In one embodiment, the hydrophobic compounds are therapeutic agents including drugs. The present invention also discloses methods for in vitro and in vivo delivery of hydrophobic compounds to cells. Uses of the methods in vitro include the testing of hydrophobic compounds for cytotoxicity. Uses of the methods in vivo include diagnostic and therapeutic purposes.Type: GrantFiled: June 4, 1993Date of Patent: December 26, 1995Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Marcel B. Bally